Chinese drugmaker CanSino Biologics started trial production of a vaccine using mRNA technology to target new variants of Covid-19 that are behind the country’s current outbreak.
This content was originally published here.
Chinese drugmaker CanSino Biologics started trial production of a vaccine using mRNA technology to target new variants of Covid-19 that are behind the country’s current outbreak.
This content was originally published here.
